Evidence map›Paper›PMID 36685606›Full record

ArticleFrontiers in immunology2022

SARS-CoV-2 antibody response after mRNA vaccination in healthcare workers with and without previous COVID-19, a follow-up study from a university hospital in Poland during 6 months 2021.

Izabella Owsianka, Agnieszka Pac, Estera Jachowicz, Karolina Gutkowska, Wiktor Szczuciński, Barbara Maziarz, Elżbieta Sochacka-Tatara, Piotr Heczko, Wojciech Sydor, Barbara Żółtowska and 1 more

Erratum issuedOpen access · goldAbstract read
In one paragraph

Article in Frontiers in immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.2field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Article
  3. Observational
  4. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Izabella OwsiankaDoctoral School of Medical and Health Sciences, Jagiellonian University Medical College, Krakow, Poland.
Agnieszka PacDepartment of Epidemiology and Preventive Medicine, Faculty of Medicine, Jagiellonian University Medical College, Krakow, Poland.
Estera JachowiczDepartment of Microbiology, Faculty of Medicine, Jagiellonian University Medical College, Krakow, Poland.
Karolina GutkowskaDepartment of Microbiology, Faculty of Medicine, Jagiellonian University Medical College, Krakow, Poland.
Wiktor SzczucińskiDepartment of Microbiology, Faculty of Medicine, Jagiellonian University Medical College, Krakow, Poland.
Barbara MaziarzDepartment of Diagnostics, Department of Clinical Biochemistry, Faculty of Medicine, Jagiellonian University Medical College, Krakow, Poland.
Elżbieta Sochacka-TataraDepartment of Epidemiology and Preventive Medicine, Faculty of Medicine, Jagiellonian University Medical College, Krakow, Poland.
Piotr HeczkoDepartment of Microbiology, Faculty of Medicine, Jagiellonian University Medical College, Krakow, Poland.
Wojciech SydorCenter for Innovative Therapy, Clinical Research Coordination Center, University Hospital in Krakow, Krakow, Poland.
Barbara ŻółtowskaCenter for Innovative Therapy, Clinical Research Coordination Center, University Hospital in Krakow, Krakow, Poland.
Jadwiga Wójkowska-MachDepartment of Microbiology, Faculty of Medicine, Jagiellonian University Medical College, Krakow, Poland.
Jagiellonian University · PLKrakow Cardiovascular Research Institute · PL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Healthcare workers (HCWs) from the beginning of the pandemic have been at risk of exposure to SARS-CoV-2, so they were vaccinated as first. Objectives: The purpose of the study was to determine the level of antibodies against SARS-CoV-2 in HCWs before and after vaccination with mRNA preparations according to previous COVID- 19. Patients and methods: The HCWs from the University Hospital in Krakow completed two surveys: the baseline survey before receiving the first dose of vaccine (in January 2021) and the follow-up survey in June 2021. In parallel, two blood samples were collected from each participant at baseline and at follow-up. Total anti-SARS-CoV-2 antibody levels were measured using the ECLIA technique. Results: At baseline, 41.1% of HCWs had positive antibody test results, and at follow-up, the vaccinated HCWs had almost 100 times higher antibody levels than the unvaccinated HCWs. Participants under 30 years of age had significantly higher antibody levels in June than older HCWs. Among participants with positive antibody test results in January, HCWs who had experienced asymptomatic COVID-19 had more than five times higher antibody levels in June than HCWs self-reported severe COVID-19. In total, 86.9% of HCWs received Comirnaty or Spikevax. The incidence rate of COVID-19 in the unvaccinated vs. vaccinated group was 13 times higher, 20.5% and 1.9% respectively. Conclusions: These results confirm the effectiveness of vaccination in the prevention of COVID-19 in HCWs. It is worth getting vaccinated regardless of previous infection. Furthermore, vaccination among HCWs under 30 years of age induced more effective antibody production compared to older individuals.

Indexed as

COVID-19Antibodies, ViralAntibody FormationFollow-Up StudiesHealth PersonnelHospitals, UniversityHumansPolandRNA, MessengerSARS-CoV-2VaccinationAntibodies, ViralRNA, Messengerantibody levelsCOVID-19COVID-19 immune responsehealthcare workersmRNA vaccine against SARS-CoV-2

Identifiers

PMID36685606
PMCPMC9850141
OpenAlexW4313550213

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.